Sign in
Taking people in South KoreaPhase 1/2

Tests RZ-001 with valganciclovir in adults with glioblastoma

Tests RZ-001 plus valganciclovir in adults with glioblastoma.

Key facts

Who runs it
Rznomics, Inc.
Where
Incheon, Seongnam-si, and Seoul, South KoreaSee the 6 sites
Trial code
Registry title
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma
Status
Recruiting
Phase
Phase 1/2
People taking part
43 people, planned
Started
8 Oct 2024
Expected to end
May 2029
Type of study
Interventional, 6 groups
Treatments tested
  • RZ-001
  • VGCV
Record updated
5 September 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a confirmed grade 4 brain tumour called glioblastoma (GBM) whose tumour shows hTERT. They would receive RZ-001 together with valganciclovir.

Age
18 years or older
Sex
All sexes can join
Disease stage
Grade 4 astrocytoma or glioblastoma (GBM), confirmed under the microscope per the 2021 WHO Classification of CNS Tumors. Life expectancy of at least 3 months.
Biomarker or test result
hTERT positive expression, confirmed during screening

Main reasons for not taking part

  • Another cancer diagnosed within the 5 years before RZ-001
  • Tumour cells that have spread outside the brain (extracranial metastases)
  • Current or past HIV positive status
  • Poor general fitness (ECOG score above 2 or KPS below 60)
  • The investigator judges that the person should not join

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Adult males and females
  • Histologically-confirmed grade 4 astrocytoma, GBM, per The 2021 WHO Classification of CNS Tumors
  • hTERT positive expression confirmed during the screening period
  • ECOG score of ≤ 2
  • KPS ≥ 60
  • Life expectancy ≥ 3 months

Who cannot take part

  • Diagnosis of other malignant tumors within 5 years prior to RZ-001 administration
  • Current or history of HIV positive
  • Have extracranial metastases of the tumor cells
  • Not suitable for inclusion judged by the investigator

Where in South Korea

  • Gachon University Gil Medical CenterIncheon, South KoreaContact: Gachon University Gil Medical CenterTaking people
  • The Catholic University of Korea, Incheon St. Mary's HospitalIncheon, South KoreaContact: The Catholic University of Korea, Incheon St. Mary's HospitalTaking people
  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Seoul National University Bundang HospitalTaking people
  • Asan Medical CenterSeoul, South KoreaContact: Asan Medical CenterTaking people
  • Samsung Medical CenterSeoul, South KoreaContact: Samsung Medical CenterTaking people
  • Severance Hospital, Yonsei University Health SystemSeoul, South KoreaContact: Severance Hospital, Yonsei University Health SystemTaking people

About the trial

What the trial wants to find out

This is a Phase 1/2a, open-label study to evaluate the safety, tolerability, immunogenicity, and preliminary clinical activity of RZ-001 administered in combination with VGCV in subjects with hTERT-positive GBM.

The 6 groups in the trial

  • Part 1 Cohort 1Treatment being tested

    RZ-001 Dose 1 and VGCV

    Treatment: RZ-001 and VGCV

  • Part 1 Cohort 2Treatment being tested

    RZ-001 Dose 2 and VGCV

    Treatment: RZ-001 and VGCV

  • Part 1 Cohort 3Treatment being tested

    RZ-001 Dose 3 and VGCV

    Treatment: RZ-001 and VGCV

  • Part 1 Cohort 4Treatment being tested

    RZ-001 Dose 4 and VGCV

    Treatment: RZ-001 and VGCV

  • Part 1 Cohort 5Treatment being tested

    RZ-001 Dose 5 and VGCV

    Treatment: RZ-001 and VGCV

  • Part 2Treatment being tested

    RZ-001 Dose 6 and VGCV

    Treatment: RZ-001 and VGCV

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2a, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, and Efficacy of RZ-001 in Combination With Valganciclovir in Subjects With Glioblastoma
Plain-language title
Tests RZ-001 with valganciclovir in adults with glioblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
5 September 2025